March 08, 2023 at 9:01 am
Protagonist Therapeutics Delivers Positive Topline Results in Psoriasis Study
Protagonist Therapeutics, Inc. (Nasdaq: PTGX) has received positive topline results in its Phase 2b FRONTIER 1 clinical trial evaluating a treatment for psoriasis. The study is being conducted in collaboration with Janssen Biotech, Inc. The company’s candidate, JNJ-2113, is an oral Interleukin-23 receptor (IL-23R) antagonist peptide. IL-23 inhibitors can help limit the inflammation that causes… [Read More]